A press release from California Trim Clinic says the reported closure of Peptide Sciences in March 2026 has renewed interest in peptide products, alternative sources, and medically supervised treatment options. The clinic, a telehealth metabolic health provider based in Westlake Village, is positioning itself as the place those customers should go next.

Peptide Sciences was an online research-peptide vendor, the kind that sells compounds labeled for laboratory use rather than human use. The release argues that people who bought from it now face questions about product integrity, regulatory status, and the line between research compounds and prescribed treatment.

Who is doing the talking

This is marketing, and it should be read that way. A clinic that sells physician-guided peptide consultations has written a document explaining why the collapse of a research-peptide supplier means you should talk to a physician, and it ends by pointing readers at a site it wants them to visit.

That does not make the underlying regulatory points wrong. It does mean the framing is doing commercial work, and a reader is entitled to notice the overlap between the problem described and the service offered.

The compound list is more honest than most

What is unusual is how little the release oversells. BPC-157 is described as frequently discussed in connection with recovery and tissue repair but not FDA-approved for human use, with adequate evidence on safety and effectiveness still lacking.

MOTS-c is called experimental with limited human evidence. CJC-1295 and ipamorelin are listed as peptides associated with growth hormone pathways where evidence for many marketed wellness uses remains limited, and NAD+ gets the same treatment.

The tesamorelin distinction

Only one compound on the list carries an approval, and the release is specific about its scope. Tesamorelin is an FDA-approved prescription medication for excess abdominal fat in adults with HIV-associated lipodystrophy, and the release states plainly that it is not approved as a general weight-loss treatment.

That sentence is the most useful one in the document, because the general weight-loss reading is exactly how tesamorelin tends to get marketed. The release also notes that compounded medications are not FDA-approved and that legal restrictions govern when substances may be compounded at all.

Bottom line

The clinic's central caution survives its own commercial interest: a supplier closing does not make the next supplier equivalent or safe, and online availability establishes nothing about quality or suitability for human use. What the release does not resolve is whether physician oversight changes the evidence base for compounds that, by its own account, do not have one yet.